Drug intelligence / Profile preview

SHR-2173

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Administration: Subcutaneous

Overview

**SHR-2173** is a subcutaneously administered therapeutic biological product currently under early clinical development for the treatment of immune-mediated diseases. Its exact mechanism of action has not been publicly disclosed, but it is described as exerting anti-inflammatory and immunosuppressive biological effects by targeting abnormally activated immune cells, aiming to reduce autoantibody levels and improve disease activity in autoimmune conditions such as systemic lupus erythematosus and possibly lupus nephritis and other related disorders. It is being developed as a new molecular entity by Guangdong Hengrui Pharmaceutical and is not yet approved in any jurisdiction[3][4][7].

Brand names: SHR-2173SHR2173SHR 2173
Other names: SHR 2173SHR2173SHR-2173

Beyond the preview

Go deeper on SHR-2173.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-2173.

Explore the full profile